MVEC has recently updated its RSV reference page with a new FAQ addressing whether there is an increased risk of preterm birth associated with RSV vaccines in pregnancy. 

Current data has not demonstrated a statistically significant risk of preterm birth associated with Abrysvo. A trial of a different RSV vaccine was halted due to a difference in the number of preterm births in the vaccine group compared with the placebo group. 

Find MVEC’s detailed answer in the ‘Commonly asked questions’ section of the MVEC:呼吸道合胞病毒(RSV) reference page, under the question ‘Is there an increased risk of preterm birth associated with RSV vaccine in pregnancy’. 

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个